

Ping Chi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2470990/publications.pdf>

Version: 2024-02-01

67
papers

6,781
citations

159585
30
h-index

114465
63
g-index

68
all docs

68
docs citations

68
times ranked

12587
citing authors

#	ARTICLE	IF	CITATIONS
1	Low-grade endometrial stromal sarcoma-like tumors in male with <i>JAZF1</i> gene fusions. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 63-70.	2.8	2
2	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. <i>Journal of Clinical Oncology</i> , 2022, 40, 997-1008.	1.6	13
3	A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 1586-1594.	7.0	20
4	Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1507-1517.	7.0	3
5	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
6	<i>FGFR2::TACC2</i> fusion as a novel <i>KIT</i> -independent mechanism of targeted therapy failure in a multidrug-resistant gastrointestinal stromal tumor. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 412-419.	2.8	4
7	Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer. <i>Nature Communications</i> , 2022, 13, 1199.	12.8	66
8	Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. , 2022, 10, e004149.		20
9	Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 939-947.	7.0	10
10	Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. <i>Science</i> , 2022, 376, .	12.6	75
11	PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. <i>Cancer Discovery</i> , 2022, 12, 2120-2139.	9.4	14
12	DICER1-Associated Anaplastic Sarcoma of the Kidney With Coexisting Activating PDGFRA D842V Mutations and Response to Targeted Kinase Inhibitors in One Patient. <i>JCO Precision Oncology</i> , 2022, , .	3.0	1
13	Combined Inhibition of G1q and MEK Enhances Therapeutic Efficacy in Uveal Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 1476-1490.	7.0	29
14	SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies. <i>Cancer Discovery</i> , 2021, 11, 1158-1175.	9.4	57
15	Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling. <i>Journal of Biological Chemistry</i> , 2021, 296, 100163.	3.4	22
16	The management of metastatic GIST: current standard and investigational therapeutics. <i>Journal of Hematology and Oncology</i> , 2021, 14, 2.	17.0	107
17	A phase 1b study of avelumab plus DCC-3014, a potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), in patients with advanced high-grade sarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11549-11549.	1.6	7
18	Melanoma models for the next generation of therapies. <i>Cancer Cell</i> , 2021, 39, 610-631.	16.8	90

#	ARTICLE	IF	CITATIONS
19	Gastrointestinal stromal tumors with <i>BRAF</i> gene fusions. A report of two cases showing low or absent <i>KIT</i> expression resulting in diagnostic pitfalls. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 789-795.	2.8	11
20	Ripretinib inpatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2021, 155, 236-244.	2.8	19
21	HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome. <i>Clinical Cancer Research</i> , 2020, 26, 5448-5455.	7.0	12
22	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. <i>Journal of Clinical Oncology</i> , 2020, 38, 3294-3303.	1.6	61
23	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. <i>JCO Precision Oncology</i> , 2020, 4, 1350-1360.	3.0	18
24	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 923-934.	10.7	224
25	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab. <i>JAMA Oncology</i> , 2020, 6, 402.	7.1	125
26	ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming. <i>Journal of Clinical Investigation</i> , 2020, 130, 5924-5941.	8.2	29
27	A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2020, 38, 11508-11508.	1.6	10
28	Association of immune-related adverse events (irAEs) with improved clinical outcome in sarcoma patients treated with immune checkpoint blockade (ICB).. <i>Journal of Clinical Oncology</i> , 2020, 38, 11510-11510.	1.6	1
29	HLA genotyping in synovial sarcoma: Identifying HLA-A*02 and its association with clinical outcome.. <i>Journal of Clinical Oncology</i> , 2020, 38, e23560-e23560.	1.6	0
30	A phase Ib study of BCG398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. <i>Investigational New Drugs</i> , 2019, 37, 282-290.	2.6	32
31	Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements. <i>Journal of Thoracic Oncology</i> , 2019, 14, 825-834.	1.1	62
32	Identification of Cancer Drivers at CTCF Insulators in 1,962 Whole Genomes. <i>Cell Systems</i> , 2019, 8, 446-455.e8.	6.2	65
33	Spindle Cell Tumors With RET Gene Fusions Exhibit a Morphologic Spectrum Akin to Tumors With NTRK Gene Fusions. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1384-1391.	3.7	78
34	Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11004-11004.	1.6	44
35	Pilot study of NKTR214 and nivolumab in patients with sarcomas.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11010-11010.	1.6	6
36	A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11049-11049.	1.6	12

#	ARTICLE	IF	CITATIONS
37	DNA damage response pathway alterations and clinical outcome in leiomyosarcoma.. Journal of Clinical Oncology, 2019, 37, 11048-11048.	1.6	7
38	Sequenced circulating tumor (ct) DNA to detect the molecular landscape in advanced GIST.. Journal of Clinical Oncology, 2019, 37, 11036-11036.	1.6	0
39	GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Reports, 2018, 22, 2455-2468.	6.4	75
40	FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor. Cancer Discovery, 2018, 8, 234-251.	9.4	49
41	A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors. Head and Neck Pathology, 2018, 12, 151-159.	2.6	23
42	COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. Journal of Clinical Investigation, 2018, 128, 1442-1457.	8.2	30
43	Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. Journal of Hematology and Oncology, 2018, 11, 78.	17.0	39
44	Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.. Journal of Clinical Oncology, 2018, 36, 11511-11511.	1.6	3
45	A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma.. Journal of Clinical Oncology, 2018, 36, 11516-11516.	1.6	6
46	Patient perspectives on ipilimumab across the melanoma treatment trajectory. Supportive Care in Cancer, 2017, 25, 2155-2167.	2.2	14
47	ETV1-Positive Cells Give Rise to <i>BRAFV600E</i> -Mutant Gastrointestinal Stromal Tumors. Cancer Research, 2017, 77, 3758-3765.	0.9	12
48	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clinical Cancer Research, 2017, 23, 2972-2980.	7.0	106
49	Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy. Ophthalmology, 2017, 124, 1788-1798.	5.2	95
50	Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell, 2017, 32, 792-806.e7.	16.8	61
51	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	1,266
52	The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2017, 35, 11010-11010.	1.6	3
53	Risk factors associated with ifosfamide (IFOS)-induced encephalopathy in patients (pts) with metastatic (Met) sarcoma (Sarc).. Journal of Clinical Oncology, 2017, 35, e22518-e22518.	1.6	1
54	A phase Ib study of BCGJ398 in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2017, 35, 11039-11039.	1.6	0

#	ARTICLE	IF	CITATIONS
55	A Trp53-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon. PLoS ONE, 2016, 11, e0161084.	2.5	18
56	Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nature Genetics, 2016, 48, 675-680.	21.4	236
57	Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib. JAMA Oncology, 2016, 2, 937.	7.1	241
58	Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape. Science, 2016, 352, 844-849.	12.6	327
59	Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab. Oral Oncology, 2016, 63, e1-e3.	1.5	11
60	Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth. Cancer Discovery, 2015, 5, 304-315.	9.4	102
61	A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. Oncologist, 2015, 20, 1245-1246.	3.7	25
62	Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature, 2015, 526, 453-457.	27.8	191
63	A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2015, 33, 10507-10507.	1.6	16
64	PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nature Genetics, 2014, 46, 1227-1232.	21.4	472
65	Organoid Cultures Derived from Patients with Advanced Prostate Cancer. Cell, 2014, 159, 176-187.	28.9	1,184
66	ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature, 2010, 467, 849-853.	27.8	279
67	Synapsin dispersion and reclustering during synaptic activity. Nature Neuroscience, 2001, 4, 1187-1193.	14.8	317